Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
23.11
-0.31 (-1.32%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Denali Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
507
Market Cap
3.67B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 330.53M | 222.07M | 204.74% |
| Dec 31, 2022 | 108.46M | 59.80M | 122.90% |
| Dec 31, 2021 | 48.66M | -287.00M | -85.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 803.79M |
| Arcutis Biotherapeutics | 415.62M |
| Arcus Biosciences | 236.00M |
| IDEAYA Biosciences | 225.27M |
| Tango Therapeutics | 56.99M |
| NewAmsterdam Pharma Company | 22.57M |
| Alumis | 8.40M |
DNLI News
- 1 day ago - Denali Therapeutics price target raised to $36 from $35 at Morgan Stanley - TheFly
- 8 days ago - Denali Therapeutics price target raised to $35 from $31 at Deutsche Bank - TheFly
- 10 days ago - Denali Therapeutics falls -14.1% - TheFly
- 10 days ago - Denali Therapeutics falls -12.4% - TheFly
- 11 days ago - Denali Therapeutics price target raised to $26 from $20 at Wedbush - TheFly
- 11 days ago - Denali Therapeutics resumed with an Overweight at JPMorgan - TheFly
- 15 days ago - Denali Therapeutics to Give Opening Plenary Address at Alzheimer's Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier - GlobeNewsWire
- 5 weeks ago - Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV - TheFly